Shots:

• Cadila has launched the adalimumab biosimilar under the brand name Cadalimab- referencing AbbVie’s Humira which is used to treat RA-PsA- AS and psoriasis
• The launch strengthens Cadila’s biosimilar portfolio as Cadalimab is the fourth biosimilar launched in the last 2mos. following Bevaro- Ritucad and NuPTH for cancer and osteoporosis
• Cadalimab is available in 40mg/0.8ml- easy pre-filled syringe and has shown a significant reduction in signs and symptoms of many diseases including RA- JIA- AS and PsA

­ Ref: Cadila  | Image: Cadila